What is Scopus Biopharma Inc.'s earnings per share (EPS)?

Scopus Biopharma Inc. (SCPS) reported diluted earnings per share of $-0.55 for fiscal year 2022. This represents a 64.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Scopus Biopharma Inc. Financials

SCPS

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2023 Currency USD FYE December

This page shows Scopus Biopharma Inc. (SCPS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating Scopus Biopharma Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Scopus Biopharma Inc. generated $0 in revenue in fiscal year 2022.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.55

YoY+64.7%

Scopus Biopharma Inc. earned $-0.55 per diluted share (EPS) in fiscal year 2022. This represents an increase of 64.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$125K

YoY-98.4%

Scopus Biopharma Inc. held $125K in cash against $0 in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

21M

YoY+0.0%

Scopus Biopharma Inc. had 21M shares outstanding in fiscal year 2022. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$2K

YoY-22.4%

Scopus Biopharma Inc. invested $2K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 22.4% from the prior year.

SCPS Income Statement

Metric	FY22	FY21	FY20	FY19
Revenue	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$15.0M+102.4%	$7.4M+1503.0%	$463K
SG&A Expenses	N/A	$12.6M+361.6%	$2.7M+22.7%	$2.2M
Operating Income	N/A	-$27.6M	N/A	-$2.7M
Interest Expense	$0-100.0%	$775K+9.7%	$706K	$0
Income Tax	N/A	N/A	N/A	N/A
Net Income	N/A	-$27.0M	N/A	-$2.7M
EPS (Diluted)	$-0.55+64.7%	$-1.56-92.6%	$-0.81	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Revenue	N/A	$0	N/A	$0	$0	$0	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.0M+23.9%	$1.6M	N/A	$917K+41.2%	$649K+76.0%	$369K	N/A	$78K
SG&A Expenses	$936K-12.6%	$1.1M	N/A	$981K-63.2%	$2.7M-37.8%	$4.3M	N/A	$2.7M
Operating Income	N/A	N/A	N/A	-$1.9M+42.8%	-$3.3M+28.8%	-$4.7M	N/A	-$2.8M
Interest Expense	N/A	N/A	N/A	$0	$0	$0	N/A	$111K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$2.4M	N/A	-$1.9M+42.8%	-$3.3M+28.8%	-$4.7M	N/A	-$1.4M
EPS (Diluted)	$-0.07+12.5%	$-0.08	N/A	$-0.09+43.8%	$-0.16+27.3%	$-0.22	N/A	$-0.08

SCPS Balance Sheet

Metric	FY22	FY21	FY20	FY19
Total Assets	$392K-95.2%	$8.2M+314.8%	$2.0M+155.8%	$772K
Current Assets	$390K-95.2%	$8.2M+315.1%	$2.0M+156.7%	$768K
Cash & Equivalents	$125K-98.4%	$7.9M+333.5%	$1.8M+4885.7%	$37K
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$7.0M+66.8%	$4.2M+9.6%	$3.8M+345.3%	$855K
Current Liabilities	N/A	$4.2M+9.6%	$3.8M+345.3%	$855K
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	-$6.6M-263.4%	$4.0M+319.4%	-$1.8M-2110.1%	-$83K
Retained Earnings	-$53.1M-28.0%	-$41.5M-185.9%	-$14.5M-298.5%	-$3.6M

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Total Assets	$498K-69.0%	$1.6M+308.7%	$392K-5.6%	$416K-75.2%	$1.7M-63.7%	$4.6M-43.7%	$8.2M+103.1%	$4.0M
Current Assets	$496K-69.0%	$1.6M+310.6%	$390K-5.6%	$413K-75.3%	$1.7M-63.7%	$4.6M-43.7%	$8.2M+103.2%	$4.0M
Cash & Equivalents	$362K-74.2%	$1.4M+1025.0%	$125K-59.9%	$311K-73.1%	$1.2M-70.9%	$4.0M-50.0%	$7.9M+118.7%	$3.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.9M+16.4%	$8.6M+22.9%	$7.0M+17.5%	$5.9M+10.2%	$5.4M+4.5%	$5.1M+23.2%	$4.2M+86.4%	$2.2M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	$4.2M+86.4%	$2.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$9.5M-36.1%	-$6.9M-5.8%	-$6.6M-19.3%	-$5.5M-48.8%	-$3.7M-597.2%	-$530K-113.2%	$4.0M+123.9%	$1.8M
Retained Earnings	-$58.1M-4.7%	-$55.5M-4.6%	-$53.1M-3.4%	-$51.3M-3.8%	-$49.4M-7.2%	-$46.1M-11.2%	-$41.5M-18.7%	-$34.9M

SCPS Cash Flow Statement

Metric	FY22	FY21	FY20	FY19
Operating Cash Flow	N/A	-$11.4M-352.4%	-$2.5M-19.1%	-$2.1M
Capital Expenditures	$2K-22.4%	$2K	$0-100.0%	$4K
Free Cash Flow	N/A	-$11.4M-352.5%	-$2.5M-18.9%	-$2.1M
Investing Cash Flow	N/A	N/A	N/A	N/A
Financing Cash Flow	$242K-98.6%	$17.6M+303.4%	$4.4M+99.3%	$2.2M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Operating Cash Flow	-$1.0M-32.8%	-$760K-80.1%	-$422K+50.5%	-$852K+70.4%	-$2.9M+27.7%	-$4.0M+4.1%	-$4.1M-64.8%	-$2.5M
Capital Expenditures	N/A	N/A	$0	$0	$0-100.0%	$2K	$0-100.0%	$2K
Free Cash Flow	N/A	N/A	-$422K+50.5%	-$852K+70.4%	-$2.9M+27.7%	-$4.0M+4.1%	-$4.1M-64.7%	-$2.5M
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$45K-102.2%	$2.0M+734.7%	$242K	$0	$0	$0-100.0%	$8.5M+8214.6%	-$105K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SCPS Financial Ratios

Metric	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	-670.9%	N/A	N/A
Return on Assets	N/A	-329.2%	N/A	-348.6%
Current Ratio	N/A	1.96+1.4	0.52-0.4	0.90
Debt-to-Equity	N/A	1.04	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-78.0%
Return on Assets	N/A	-152.8%	N/A	-456.8%-258.3pp	-198.4%-97.3pp	-101.2%	N/A	-34.7%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	1.96+0.2	1.80
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	1.04-0.2	1.25
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$6.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Virpax Pharmaceuticals Inc VRPX

$5.7M

Q Biomed QBIO

$15K

Biostax Corp BTAX

$16K

Evelo Biosciences EVLO

$9K

Renovacare RCAR

$9K

Frequently Asked Questions

What is Scopus Biopharma Inc.'s annual revenue?

Scopus Biopharma Inc. (SCPS) reported $0 in total revenue for fiscal year 2022. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

What are Scopus Biopharma Inc.'s total assets?

Scopus Biopharma Inc. (SCPS) had $392K in total assets as of fiscal year 2022, including both current and long-term assets.

What are Scopus Biopharma Inc.'s capital expenditures?

Scopus Biopharma Inc. (SCPS) invested $2K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How many shares does Scopus Biopharma Inc. have outstanding?

Scopus Biopharma Inc. (SCPS) had 21M shares outstanding as of fiscal year 2022.

Why is Scopus Biopharma Inc.'s debt-to-equity ratio negative or not reported?

Scopus Biopharma Inc. (SCPS) has negative shareholder equity of -$6.6M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.